Clinical Study

Stro-002-Gm1 A Phase 1 Open-Label, Safety, Pharmacokinetic And Preliminary Efficacy Study Of Stro-002, An Anti-Folate Receptor Alpha (Folra) Antibody-Drug Conjugate (Adc), In Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube Or Pr

Posted Date: Jul 6, 2021

  • Investigator: Amanda Jackson
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The primary objective of this study is to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks. Efficacy will be measured by the Incidence of Treatment-Emergent Adverse Events and evaluating preliminary anti-tumor activity. Patients in the experimental arm will receive STRO-002 treatment at increasing dose levels through IV antibody drug conjugate.


Participants Must Have Evidence Of Measureable Disease As Defined By Recist 1.1, Must Have Ecog Performance Status Of 0-1, Must Have Qtcf <500 Msec. No Low Grade Ovarian Carcinoma. No Clear Cell, Mucinous And Sarcomatous Ovarian Carcinomas. No Prior Treatment With A Folra-Targeting Adcs Or Folra-Targeting Vaccines. No Subjects Who Are Platinum-Refractory During Frontline Treatment. No Prior Anticancer Therapy. No Clinically Significant Pre-Exisiting Ocular Disorders. No Sensory Or Motor Neuropathy = Grade 2.


Phase 1, Ovarian, Endometrial

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.